Acute Coronary Syndrome: Focus on Antiplatelet Therapy
Abstract
The American Heart Association/American College of Cardiology in 2014 published a focused update of the 2007 and 2012 guidelines for non–ST-segment elevation acute coronary syndrome (NSTE-ACS). The management of ST-segment elevation myocardial infarction (STEMI) is described in a separate guideline published in 2013. The focused updates to the guidelines contain updated recommendations for dual antiplatelet therapy, including use of the P2Y12 inhibitor ticagrelor, which was recently approved by the Food and Drug Administration. Nurses caring for patients with acute coronary syndrome must have a good understanding of the current treatment guidelines for such patients, to help ensure delivery of evidence-based care. This review article uses a case study–based approach to describe how the new guidelines affect clinical decision making when choosing appropriate antiplatelet therapy for patients with NSTE-ACS or STEMI, depending on the patient’s clinical history and presenting characteristics.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antiplatelet agents reduce cardiovascular events and mortality, but their wider use is limited by increased bleeding risk and nonadherence.
“Use of antiplatelet agents has become a cornerstone for the treatment of CVD because of substantial reduction in CVD events and mortality37,38. However, more widespread use of antiplatelet agents has been limited by the increased risk of bleeding, which also leads to nonadherence39–41.”
From Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential (2018) · cites this paper as [37]
The citation lists haven’t been fetched yet
References 57 · Cited by 15
- Authors
- Bobadilla, R. V.
- Affiliations
- University of South Carolina (US)
- Corresponding author
- Bobadilla, Rodel V.
- Venue
- Critical Care Nurse
- Publisher
- AACN Publishing
- Published
- 2016-02-01
- Volume
- 36
- Issue
- 1
- Pages
- 15-27
- ISSN
- 0279-5442 (ISSN-L)
- 1940-8250
- OpenAlex
- W2253352525
- Cited by
- 15
- References
- 57
- Citations by year
- 2023: 1 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 3
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Nurse (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- American College of Cardiology Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
- Keywords
- acute coronary syndrome, antiplatelet therapy, dual antiplatelet therapy, P2Y12 inhibitors, ticagrelor, non-ST-elevation acute coronary syndrome, ST-elevation myocardial infarction, evidence-based nursing, clinical decision-making
- MeSH terms
- Humans, Platelet Aggregation Inhibitors, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
